Elite Pharmaceuticals Inc (ELTP)

[Couch]

Imagine what it would be worth if the FDA approved it

ANSWER: LMAO; a whole lot more than $1 billion dollars.

Remind me again how many of the previous 3 companies Nasrat worked for got bought out.

ANSWER: 100% of them.

Remind me again how many FDA ADT labeled IR opioids on the market again.

ANSWER: ZERO

Remind me again the percentage of prescribed opioids that are immediate release.

ANSWER: 91%

Remind me again the percentage of prescribed opioids that are ADT.

ANSWER: 2%

Remind me again the percentage of opioids that the FDA states it wants to prescribe bet are abuse deterrent.

ANSWER: greater than 50%

Remind me again who the biggest pharmaceutical company is on the planet.

ANSWER: Pfizer

Remind me again who has the same exact one bead technology as Pfizer - in addition to a 2 bead technology Pfizer does not have.

ANSWER: Elite

Remind me how many generic ADT opioids on the market.

ANSWER: ZERO

REMIND me again who is the only company that has the ADT technolgy to make generic ADT products of Pfizer's branded OPIOID products.

ANSWER: Elite

Remind me again what savvy investors are doing based on this savvy DD.

ANSWER: continuing to BUY HOLD & ACCUMULATE.

Elite Provides Update on SequestOx™ New Drug Application
NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the "FDA") on December 21, 2016 for an end-of-review meeting to discuss steps that Elite can take to obtain approval of SequestOx™. Based on the FDA response, the Company believes there is a clear path forward to address the issues cited in the July 14th Complete Response Letter ("CRL"). The FDA will provide minutes of the meeting by the end of January and the Company will issue a further update at that time.

SequestOx™ (oxycodone hydrochloride and naltrexone hydrochloride) is Elite's investigational abuse-deterrent opioid candidate for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. The proposed plan submitted by the Company addresses items cited in the CRL dated July 14, 2016 for the New Drug Application (the "NDA") for SequestOx™.

"We are extremely pleased that there is a path forward to seek FDA approval of SequestOx™," said Nasrat Hakim, President and CEO of Elite. "Based on the guidance received from the agency, Elite will begin to execute the proposed plan immediately."